EP4096649A4 - COMPOUNDS AND METHODS FOR PROVIDING CHEMOPROTECTIVE EFFECTS - Google Patents

COMPOUNDS AND METHODS FOR PROVIDING CHEMOPROTECTIVE EFFECTS Download PDF

Info

Publication number
EP4096649A4
EP4096649A4 EP21747296.8A EP21747296A EP4096649A4 EP 4096649 A4 EP4096649 A4 EP 4096649A4 EP 21747296 A EP21747296 A EP 21747296A EP 4096649 A4 EP4096649 A4 EP 4096649A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
providing
chemoprotective effects
chemoprotective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21747296.8A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4096649A1 (en
Inventor
Serhat GUMRUKCU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
G Tech Bio LLC
Original Assignee
G Tech Bio LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G Tech Bio LLC filed Critical G Tech Bio LLC
Publication of EP4096649A1 publication Critical patent/EP4096649A1/en
Publication of EP4096649A4 publication Critical patent/EP4096649A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/02—Acid—amino-acid ligases (peptide synthases)(6.3.2)
    • C12Y603/02002—Glutamate-cysteine ligase (6.3.2.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/53—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP21747296.8A 2020-01-31 2021-02-01 COMPOUNDS AND METHODS FOR PROVIDING CHEMOPROTECTIVE EFFECTS Pending EP4096649A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062968906P 2020-01-31 2020-01-31
PCT/US2021/016041 WO2021155351A1 (en) 2020-01-31 2021-02-01 Compositions and methods for providing chemoprotective effects

Publications (2)

Publication Number Publication Date
EP4096649A1 EP4096649A1 (en) 2022-12-07
EP4096649A4 true EP4096649A4 (en) 2024-04-17

Family

ID=77079986

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21747296.8A Pending EP4096649A4 (en) 2020-01-31 2021-02-01 COMPOUNDS AND METHODS FOR PROVIDING CHEMOPROTECTIVE EFFECTS

Country Status (4)

Country Link
EP (1) EP4096649A4 (https=)
JP (1) JP2023512287A (https=)
CN (1) CN115605084A (https=)
WO (1) WO2021155351A1 (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020195A1 (en) * 1992-04-01 1993-10-14 Fox Chase Cancer Center Method and recombinant cells for providing increased resistance of hematopoietic progenitor cells to toxicity of chemotherapeutic agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109168A0 (en) * 1993-04-01 1994-06-24 Univ Columbia A retroviral vector capable of transducing the aldehyde dehydrogenase-1 gene and making cells resistant to the chemotherapeutic agent cyclophosphamide and its derivatives and analogs
WO2015009884A1 (en) * 2013-07-18 2015-01-22 The Hamner Institutes Cell culture media formulations comprising an activator of nad-dependent protein deacteylase and ueses thereof
IL274632B2 (en) * 2017-11-15 2024-12-01 Weird Science Llc Methods and compositions for non-myeloablative bone marrow reconstitution
CA3106403A1 (en) * 2018-07-15 2020-01-23 Enochian BioPharma, Inc. Methods and compositions using recombinant dendritic cells for cancer therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020195A1 (en) * 1992-04-01 1993-10-14 Fox Chase Cancer Center Method and recombinant cells for providing increased resistance of hematopoietic progenitor cells to toxicity of chemotherapeutic agents

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
BOTTA DIANNE ET AL: "Glutamate-cysteine ligase attenuates TNF-induced mitochondrial injury and apoptosis", FREE RADICAL BIOLOGY & MEDICINE, vol. 37, no. 5, 1 September 2004 (2004-09-01), pages 632 - 642, ISSN: 0891-5849 *
BOTTA DIANNE ET AL: "Modulating GSH Synthesis Using Glutamate Cysteine Ligase Transgenic and Gene-Targeted Mice", vol. 40, no. 3, 9 January 2008 (2008-01-09), UNITED STATES, pages 465 - 477, XP093101728, ISSN: 0360-2532, Retrieved from the Internet <URL:http://dx.doi.org/10.1080/03602530802186587> DOI: 10.1080/03602530802186587 *
CORTES-WANSTREET MABEL M ET AL: "Overexpression of glutamate-cysteine ligase protects human COV434 granulosa tumour cells against oxidative and gamma-radiation-induced cell death.", MUTAGENESIS MAY 2009, vol. 24, no. 3, May 2009 (2009-05-01), pages 211 - 224, ISSN: 1464-3804 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1 September 2004 (2004-09-01), BOTTA DIANNE ET AL: "Glutamate-cysteine ligase attenuates TNF-induced mitochondrial injury and apoptosis", Database accession no. PREV200400394547 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2003 (2003-11-01), INOUE YOSHIMASA ET AL: "The modifier subunit of glutamate cysteine ligase (GCLM) is a molecular target for amelioration of cisplatin resistance in lung cancer.", Database accession no. PREV200300537277 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; September 2008 (2008-09-01), CHEN HELEN H W ET AL: "Elevated glutathione levels confer cellular sensitization to cisplatin toxicity by up-regulation of copper transporter hCtr1", Database accession no. PREV200800617554 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; September 2013 (2013-09-01), BACKOS DONALD S ET AL: "Glycation of Glutamate Cysteine Ligase by 2-Deoxy-D-Ribose and its Potential Impact on Chemoresistance in Glioblastoma", Database accession no. PREV201300632181 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; February 2009 (2009-02-01), MOHAR ISAAC ET AL: "Glutamate cysteine ligase (GCL) transgenic and gene-targeted mice for controlling glutathione synthesis.", Database accession no. NLM23045016 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; May 2009 (2009-05-01), CORTES-WANSTREET MABEL M ET AL: "Overexpression of glutamate-cysteine ligase protects human COV434 granulosa tumour cells against oxidative and gamma-radiation-induced cell death.", Database accession no. NLM19153097 *
G�MR�KC� SERHAT ET AL: "Glutamate-Cysteine Ligase Modifier Subunit Overexpression Confers Resistance Against Busulfan", 1 May 2022 (2022-05-01), XP093101680, Retrieved from the Internet <URL:https://seraphinstitute.org/wp-content/uploads/2022/03/Publication10.pdf> [retrieved on 20231115] *
HARKEY M A ET AL: "OVEREXPRESSION OF GLUTATHIONE-S-TRANSFERASE, MGSTII, CONFERS RESISTANCE TO BUSULFAN AND MELPHALAN", CANCER INVESTIGATION, TAYLOR & FRANCIS INC, US, vol. 23, no. 1, 1 January 2005 (2005-01-01), pages 19 - 25, XP009053374, ISSN: 0735-7907 *
HIYAMA NORIKO ET AL: "Glutamate-cysteine ligase catalytic subunit is associated with cisplatin resistance in lung adenocarcinoma", vol. 48, no. 4, 1 April 2018 (2018-04-01), pages 303 - 307, XP093101749, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892860/pdf/hyy013.pdf> DOI: 10.1093/jjco/hyy013 *
INOUE YOSHIMASA ET AL: "The modifier subunit of glutamate cysteine ligase (GCLM) is a molecular target for amelioration of cisplatin resistance in lung cancer.", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 23, no. 5, November 2003 (2003-11-01), pages 1333 - 1339, ISSN: 1019-6439 *
MOHAR ISAAC ET AL: "Glutamate cysteine ligase (GCL) transgenic and gene-targeted mice for controlling glutathione synthesis.", CURRENT PROTOCOLS IN TOXICOLOGY FEB 2009, vol. Chapter 6, February 2009 (2009-02-01), pages Unit6.16, ISSN: 1934-9262 *
MOLECULAR PHARMACOLOGY, vol. 74, no. 3, September 2008 (2008-09-01), pages 697 - 704, ISSN: 0026-895X, DOI: 10.1124/MOL.108.047969 *
NEUROCHEMICAL RESEARCH, vol. 38, no. 9, September 2013 (2013-09-01), pages 1838 - 1849, ISSN: 0364-3190(print), DOI: 10.1007/S11064-013-1090-4 *
See also references of WO2021155351A1 *

Also Published As

Publication number Publication date
CN115605084A (zh) 2023-01-13
WO2021155351A1 (en) 2021-08-05
JP2023512287A (ja) 2023-03-24
EP4096649A1 (en) 2022-12-07

Similar Documents

Publication Publication Date Title
AU2022344251A1 (en) Serpina-modulating compositions and methods
AU2022342169A1 (en) Hbb-modulating compositions and methods
EP4185569A4 (en) METHODS AND COMPOSITIONS FOR TARGETING PD-L1
AU2021399009A9 (en) Isocycloseram formulation
AU2022342168A1 (en) Pah-modulating compositions and methods
EP4212162A4 (en) LIPID COMPOSITION
EP4096649A4 (en) COMPOUNDS AND METHODS FOR PROVIDING CHEMOPROTECTIVE EFFECTS
EP4288062A4 (en) FOSPROPOFOL METHODS AND COMPOSITIONS
HK40114697A (en) Methods and compositions for avoiding off-target effects
HK40114372A (en) Serpina-modulating compositions and methods
HK40114694A (en) Pah-modulating compositions and methods
HK40114695A (en) Hbb-modulating compositions and methods
HK40111907A (en) Methods and compositions
AU2024259472A1 (en) Compositions and methods for immunotherapy - ii
AU2021900201A0 (en) Compositions and methods
HK40114316A (en) Methods and compositions for microencapsulated compounds
EP4373507A4 (en) METHODS AND COMPOSITIONS FOR MICROENCAPSULED COMPOUNDS
AU2020904390A0 (en) Compositions and methods
AU2020902486A0 (en) Methods and compositions
AU2020901237A0 (en) Methods and compositions
HK40110736A (en) Methods and compositions for improved immunotherapies
AU2020900084A0 (en) Compositions and methods
AU2020900083A0 (en) Compositions and methods
HK40101534A (en) Compositions and methods for enhancing visual function
HK40115055A (en) Novel anellovector compositions and methods

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220830

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230516

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: G TECH BIO LLC

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GUMRUKCU, SERHAT

A4 Supplementary search report drawn up and despatched

Effective date: 20240315

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/52 20060101ALI20240311BHEP

Ipc: C12N 9/00 20060101ALI20240311BHEP

Ipc: A61K 38/53 20060101ALI20240311BHEP

Ipc: A61K 35/12 20150101ALI20240311BHEP

Ipc: A61K 31/255 20060101AFI20240311BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20241206